Rational use of analgesic and antiinflammatory drugs. Crofford LJ (2001) N Engl J Med 345: 1844-6 COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) Lancet 360: 1071-3 Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ (1998) Science 280: 1268-70 Human lupus T cells resist inactivation and escape death by upregulating COX-2. Xu L, Zhang L, Yi Y, Kang HK, Datta SK (2004) Nat Med 10: 411-5 The COXIB experience: a look in the rearview mirror. Marnett LJ (2009) Annu Rev Pharmacol Toxicol 49: 265-90 COX-2: a target for colon cancer prevention. Marnett LJ, DuBois RN (2002) Annu Rev Pharmacol Toxicol 42: 55-80 Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF (2002) Circulation 105: 1816-23 Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR (2001) Circulation 104: 820-5 (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD, Banerjee S, Oates JA, Marnett LJ (2011) Nat Chem Biol 7: 803-9 Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Gastroenterology 120: 1713-9 Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR (2007) Gastroenterology 133: 790-8 Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN (1997) J Clin Invest 99: 2254-9 Aspirin use and potential mechanisms for colorectal cancer prevention. Williams CS, Smalley W, DuBois RN (1997) J Clin Invest 100: 1325-9 Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. Zhang MZ, Xu J, Yao B, Yin H, Cai Q, Shrubsole MJ, Chen X, Kon V, Zheng W, Pozzi A, Harris RC (2009) J Clin Invest 119: 876-85 Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD (2002) J Clin Invest 110: 61-9 Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. Hao CM, Yull F, Blackwell T, Kömhoff M, Davis LS, Breyer MD (2000) J Clin Invest 106: 973-82 Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, Harris RC (1999) J Clin Invest 103: 953-61 Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ (2000) Proc Natl Acad Sci U S A 97: 925-30 Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD (1997) Proc Natl Acad Sci U S A 94: 657-62 Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Reese J, Paria BC, Brown N, Zhao X, Morrow JD, Dey SK (2000) Proc Natl Acad Sci U S A 97: 9759-64 Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Marnett LJ, Kalgutkar AS (1998) Curr Opin Chem Biol 2: 482-90 Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Marnett LJ, Kalgutkar AS (1999) Trends Pharmacol Sci 20: 465-9 Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S (2014) Trends Pharmacol Sci 35: 358-67 Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR (2013) Ann Rheum Dis 72: 1813-8 Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Cancer Res 58: 362-6 Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ (2003) Cancer Res 63: 1748-51 Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ (2010) Cancer Res 70: 3618-27 Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD (1998) Cancer Res 58: 2323-7 Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Cancer Res 59: 4574-7 Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Cancer Res 60: 6045-51 A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Wang JL, Cheng HF, Shappell S, Harris RC (2000) Kidney Int 57: 2334-42 Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kömhoff M, Wang JL, Cheng HF, Langenbach R, McKanna JA, Harris RC, Breyer MD (2000) Kidney Int 57: 414-22 Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC (2002) Kidney Int 62: 929-39 A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H (2009) Clin Cancer Res 15: 2158-65 Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB (2000) Arthritis Rheum 43: 4-13 Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH (2000) Arthritis Rheum 43: 1891-6 The role of cyclooxygenases in inflammation, cancer, and development. Williams CS, Mann M, DuBois RN (1999) Oncogene 18: 7908-16 Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Wang JL, Cheng HF, Harris RC (1999) Hypertension 34: 96-101 Cyclooxygenases, the kidney, and hypertension. Cheng HF, Harris RC (2004) Hypertension 43: 525-30 Meloxicam inhibits the growth of colorectal cancer cells. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN (1998) Carcinogenesis 19: 2195-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.